These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 39362905)

  • 1. Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones.
    Ianevski A; Nader K; Driva K; Senkowski W; Bulanova D; Moyano-Galceran L; Ruokoranta T; Kuusanmäki H; Ikonen N; Sergeev P; Vähä-Koskela M; Giri AK; Vähärautio A; Kontro M; Porkka K; Pitkänen E; Heckman CA; Wennerberg K; Aittokallio T
    Nat Commun; 2024 Oct; 15(1):8579. PubMed ID: 39362905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and functional landscape of malignant serous effusions for precision oncology.
    Wegmann R; Bankel L; Festl Y; Lau K; Lee S; Arnold F; Cappelletti V; Fehr A; Picotti P; Dedes KJ; Franzen D; Lenggenhager D; Bode PK; Zoche M; Moch H; Britschgi C; Snijder B
    Nat Commun; 2024 Oct; 15(1):8544. PubMed ID: 39358333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of Pan-Cancer Cell Line and Single-Cell Transcriptomic Profiles Enables Inference of Therapeutic Vulnerabilities in Heterogeneous Tumors.
    Zhang W; Maeser D; Lee A; Huang Y; Gruener RF; Abdelbar IG; Jena S; Patel AG; Huang RS
    Cancer Res; 2024 Jun; 84(12):2021-2033. PubMed ID: 38581448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer.
    He L; Bulanova D; Oikkonen J; Häkkinen A; Zhang K; Zheng S; Wang W; Erkan EP; Carpén O; Joutsiniemi T; Hietanen S; Hynninen J; Huhtinen K; Hautaniemi S; Vähärautio A; Tang J; Wennerberg K; Aittokallio T
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34343245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors.
    Sinha S; Vegesna R; Mukherjee S; Kammula AV; Dhruba SR; Wu W; Kerr DL; Nair NU; Jones MG; Yosef N; Stroganov OV; Grishagin I; Aldape KD; Blakely CM; Jiang P; Thomas CJ; Benes CH; Bivona TG; Schäffer AA; Ruppin E
    Nat Cancer; 2024 Jun; 5(6):938-952. PubMed ID: 38637658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
    Pemovska T; Kontro M; Yadav B; Edgren H; Eldfors S; Szwajda A; Almusa H; Bespalov MM; Ellonen P; Elonen E; Gjertsen BT; Karjalainen R; Kulesskiy E; Lagström S; Lehto A; Lepistö M; Lundán T; Majumder MM; Marti JM; Mattila P; Murumägi A; Mustjoki S; Palva A; Parsons A; Pirttinen T; Rämet ME; Suvela M; Turunen L; Västrik I; Wolf M; Knowles J; Aittokallio T; Heckman CA; Porkka K; Kallioniemi O; Wennerberg K
    Cancer Discov; 2013 Dec; 3(12):1416-29. PubMed ID: 24056683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
    J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-Resistant Epithelial Ovarian Cancer: Current and Future Perspectives.
    Mehrotra M; Phadte P; Shenoy P; Chakraborty S; Gupta S; Ray P
    Adv Exp Med Biol; 2024; 1452():65-96. PubMed ID: 38805125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia.
    Lee SI; Celik S; Logsdon BA; Lundberg SM; Martins TJ; Oehler VG; Estey EH; Miller CP; Chien S; Dai J; Saxena A; Blau CA; Becker PS
    Nat Commun; 2018 Jan; 9(1):42. PubMed ID: 29298978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized therapy for acute myeloid leukemia.
    Hourigan CS; Karp JE
    Cancer Discov; 2013 Dec; 3(12):1336-8. PubMed ID: 24327695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-tailored design for selective co-inhibition of leukemic cell subpopulations.
    Ianevski A; Lahtela J; Javarappa KK; Sergeev P; Ghimire BR; Gautam P; Vähä-Koskela M; Turunen L; Linnavirta N; Kuusanmäki H; Kontro M; Porkka K; Heckman CA; Mattila P; Wennerberg K; Giri AK; Aittokallio T
    Sci Adv; 2021 Feb; 7(8):. PubMed ID: 33608276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia.
    Qin G; Dai J; Chien S; Martins TJ; Loera B; Nguyen QH; Oakes ML; Tercan B; Aguilar B; Hagen L; McCune J; Gelinas R; Monnat RJ; Shmulevich I; Becker PS
    Clin Cancer Res; 2024 Jun; 30(12):2659-2671. PubMed ID: 38619278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deconvolution of cell type-specific drug responses in human tumor tissue with single-cell RNA-seq.
    Zhao W; Dovas A; Spinazzi EF; Levitin HM; Banu MA; Upadhyayula P; Sudhakar T; Marie T; Otten ML; Sisti MB; Bruce JN; Canoll P; Sims PA
    Genome Med; 2021 May; 13(1):82. PubMed ID: 33975634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy.
    Shee K; Wells JD; Jiang A; Miller TW
    PLoS One; 2019; 14(11):e0224267. PubMed ID: 31682620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in
    Färkkilä A; Rodríguez A; Oikkonen J; Gulhan DC; Nguyen H; Domínguez J; Ramos S; Mills CE; Pérez-Villatoro F; Lazaro JB; Zhou J; Clairmont CS; Moreau LA; Park PJ; Sorger PK; Hautaniemi S; Frias S; D'Andrea AD
    Cancer Res; 2021 May; 81(10):2774-2787. PubMed ID: 33514515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance.
    Pietilä EA; Gonzalez-Molina J; Moyano-Galceran L; Jamalzadeh S; Zhang K; Lehtinen L; Turunen SP; Martins TA; Gultekin O; Lamminen T; Kaipio K; Joneborg U; Hynninen J; Hietanen S; Grénman S; Lehtonen R; Hautaniemi S; Carpén O; Carlson JW; Lehti K
    Nat Commun; 2021 Jun; 12(1):3904. PubMed ID: 34162871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
    Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell transcriptome analysis of macrophage subpopulations contributing to chemotherapy resistance in ovarian cancer.
    Zhong X; Zhang F; Xiao H; Tu R
    Immunobiology; 2024 Sep; 229(5):152811. PubMed ID: 38941863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy.
    Huang C; Clayton EA; Matyunina LV; McDonald LD; Benigno BB; Vannberg F; McDonald JF
    Sci Rep; 2018 Nov; 8(1):16444. PubMed ID: 30401894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.